首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis
【24h】

Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis

机译:靶向SMAD5将microRNA-155连接到TGF-β途径和淋巴瘤发生

获取原文
获取原文并翻译 | 示例
       

摘要

The mechanisms by which microRNA dysfunction contributes to the pathogenesis of diffuse large B cell lymphoma (DLBCL) are not well established. The identification of the genes and pathways directly targeted by these small regulatory RNAs is a critical step to advance this field. Using unbiased genome-wide approaches in DLBCL we discovered that the oncogenic microRNA-155 (miR-155) directly targets the bone morphogenetic protein (BMP)-responsive transcriptional factor SMAD5. Surprisingly, we found that in DLBCL a noncanonical signaling module linking TGF-β1 signals to SMAD5 is also active. In agreement with these data, miR-155 overexpression rendered DLBCLs resistant to the growth-inhibitory effects of both TGF-β1 and BMPs, via defective induction of p21 and impaired cell cycle arrest. In confirmatory experiments, RNAi-based SMAD5 knockdown recapitulated in vitro and in vivo the effects miR-155 overexpression. Furthermore, in primary DLBCLs, miR-155 overexpression inhibited SMAD5 expression and disrupted its activity, as defined by individual and global analyses of its transcriptional targets. Together, our data helped explain miR-155 function, highlighted a hitherto unappreciated role of SMAD5 in lymphoma biology, and defined a Unique mechanism used by cancer cells to escape TGF-β's growth-inhibitory effects.
机译:microRNA功能障碍导致弥漫性大B细胞淋巴瘤(DLBCL)发病机理的机制尚不十分清楚。这些小调节RNA直接靶向的基因和途径的鉴定是推进该领域的关键步骤。在DLBCL中使用无偏见的全基因组方法,我们发现致癌的microRNA-155(miR-155)直接靶向骨形态发生蛋白(BMP)响应转录因子SMAD5。出乎意料的是,我们发现在DLBCL中,将TGF-β1信号链接至SMAD5的非规范信号模块也处于活动状态。与这些数据相一致,miR-155的过表达使p21的诱导缺陷和细胞周期停滞受损,从而使DLBCL对TGF-β1和BMP的生长抑制作用具有抗性。在验证性实验中,基于RNAi的SMAD5组合在体外和体内概括了miR-155过表达的作用。此外,在原发性DLBCL中,miR-155的过表达抑制SMAD5的表达并破坏其活性,这是根据其转录靶点的单独和整体分析确定的。在一起,我们的数据有助于解释miR-155的功能,突出了SMAD5在淋巴瘤生物学中迄今未曾发挥的作用,并定义了癌细胞逃避TGF-β的生长抑制作用的独特机制。

著录项

  • 来源
  • 作者单位

    Division of Hematology and Medical Oncology, Department of Medicine, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX 78229;

    rnDivision of Hematology and Medical Oncology, Department of Medicine, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX 78229;

    rnDivision of Hematology and Medical Oncology, Department of Medicine, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX 78229;

    rnDivision of Hematology and Medical Oncology, Department of Medicine, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX 78229;

    rnDivision of Hematology and Medical Oncology, Department of Medicine, Cancer Therapy and Research Center at the University of Texas Health Science Center, San Antonio, TX 78229;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    lymphoma; miR-155; transforming growth factor β; B lymphocytes; bone morphogenetic protein;

    机译:淋巴瘤miR-155;转化生长因子β;B淋巴细胞;骨形态发生蛋白;
  • 入库时间 2022-08-18 00:41:13

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号